News

Barinthus Bio Achieves Key Clinical Milestones in 2024

Barinthus Bio Achieves Key Clinical Milestones in 2024

Barinthus Bio Announces Progress and Financial Highlights

Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company, has made notable strides in its clinical trials and delivered its financial updates for the third quarter of 2024. The company focuses on innovative immunotherapeutic candidates designed to guide T cells in controlling diseases.

Advancements in Clinical Trials

Dr. Leon Hooftman, Chief Medical Officer of Barinthus Bio, shared insights into the company's impressive execution in clinical trials. Notably, the enrollment for the HBV003 trial of VTP-300 targeting chronic hepatitis B has been completed, covering 121 adult participants. This Phase 2b trial aims to gather vital dosing information for a potential functional cure, as participants receive VTP-300 alongside low-dose nivolumab.

Promising Data from VTP-300

Earlier this year, interim results from the HBV003 trial showcased positive outcomes presented at the European Association for the Study of the Liver (EASL) Congress. The results indicated that VTP-300, when combined with low-dose nivolumab, was generally well-tolerated and led to a significant decline in Hepatitis B surface antigen levels. Impressively, 76% of participants assessed for nucleos(t)ide analogue (NUC) therapy discontinuation met necessary criteria at week 24 or later.

Initiation of VTP-1000 Trials for Celiac Disease

In another significant development, the company has kick-started the first-in-human Phase 1 AVALON trial of VTP-1000 in adults with celiac disease. This randomized and placebo-controlled clinical trial includes a gluten challenge to evaluate the drug's safety and tolerability.

Financial Performance and Future Outlook

As of October 2024, Barinthus Bio reported a cash position of $106.1 million, down from $117.8 million at the end of June. The net cash used in operating activities was $18.2 million for the third quarter, primarily due to ongoing clinical trials, although some was offset by gains from foreign exchange rates.

Revenue Growth

The revenue for the third quarter reflected positive growth, totaling $15.0 million, compared to zero earnings reported in the prior quarter. This increase is attributed to Barinthus Bio's share of royalties related to Vaxzevria commercial sales.

Looking Ahead: Key Upcoming Milestones

In the fourth quarter of 2024, the company anticipates delivering updated data from the VTP-300 program, with ongoing clinical trials to be reviewed at the AASLD – The Liver Meeting scheduled for mid-November.

Anticipated Data from Other Trials

The company is also looking forward to releasing data from the AVALON trial of VTP-1000 in celiac disease in the first half of 2025. Additionally, results from the PCA001 trial for VTP-850 targeting prostate cancer are expected in the same timeframe.

Summary of the Third Quarter Financial Highlights

Direct Research and Development Expenses

The direct research and development expenses totaled $6.514 million for the quarter. This signifies a tight management of resources while still focusing on advancing the pivotal trials.

General and Administrative Expenses

The third quarter also saw general and administrative expenses rise to $13.4 million, significantly impacted by foreign exchange losses. This reflects ongoing operational adjustments as the company navigates its fiscal landscape.

About Barinthus Bio

Barinthus Bio is dedicated to developing novel immunotherapeutic solutions aimed at treating chronic infectious diseases and autoimmune disorders. The commitment to enhancing patient lives and advancing medical science remains at the forefront of their mission.

Frequently Asked Questions

What are the recent clinical trials Barinthus Bio has initiated?

Barinthus Bio recently completed enrollment in the HBV003 trial for VTP-300 and commenced the AVALON trial for VTP-1000.

What financial position does Barinthus Bio currently hold?

As of the latest financial update, Barinthus Bio holds a cash balance of $106.1 million and reported revenues of $15 million this quarter.

How does Barinthus Bio's pipeline look for future developments?

The company has several crucial milestones upcoming in 2024 and 2025, particularly regarding its products targeting chronic hepatitis B, celiac disease, and prostate cancer.

What are the company's main therapeutic focuses?

Barinthus Bio is focused on developing immunotherapies for chronic infectious diseases and autoimmune conditions, notably for hepatitis B and celiac disease.

How can investors learn more about Barinthus Bio's updates?

Investors are encouraged to monitor the company's website and their social media for the latest non-public information and updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ouma Connect Streamlines Surrogacy Medical Clearance

Updated Category News Views 113

A Game Changer for Surrogacy Agencies When we talk about innovation, we often focus on the flashiest tech in finance or the buzz of a scorching hot stock. But here's Ouma Health, shifting gears in a sector many traders don't blink at—surrogacy. They're unveiling Ouma Connect, a portal pulling back the curtain on medical clearances for gestational-carrier candidates....

Continue Reading
ASICS and University of Michigan Launch Innovation Lab

Updated Category News Views 104

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Continue Reading
Utopia Bagels Honored at 2026 New York BagelFest

Updated Category News Views 106

From Queens Streets to Global Fame Try to picture this: a small neighborhood shop where the scent of freshly baked bagels wafts through, bringing together old friends and new generations. Now, take that local magic and multiply it by a global stage. That's the journey Utopia Bagels from Queens stepped into with massive strides over 45 years, earning a celebrated spot in...

Continue Reading
Medline's Decade-Long WRAP Partnership: More Than Labels

Updated Category News Views 86

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Continue Reading
Touchmark's Q3 Bonanza: Income Leaps 39%, Stock Repurchase

Updated Category News Views 24

Ever seen a bank juggle financials like a street performer with flaming torches? That's Touchmark Bancshares for you this quarter. This Georgia-based community bank just released their third quarter 2026 results, and it seems they've not only mastered performance but also pranced around market risks effortlessly, much to the delight of investors. Breaking Down the Numbers...

Continue Reading
Huntington Bank Bolsters Westside Future Fund with $1M Boost

Updated Category News Views 39

Huntington's Commitment Goes Beyond Dollars In a world where corporations often toss out pretty phrases without the substance to back them up, Huntington Bank's $1 million shout-out to Atlanta's Westside Future Fund (WFF) speaks volumes. This ain't your run-of-the-mill PR move. It's a solid, tangible effort to help a community that's rich in history but screaming for...

Continue Reading
Unlock Technologies Secures $433.1M in HEA Securitization

Updated Category News Views 147

An Unconventional Wave of Funding Ain't it a sight to see? One year you're hawking tech stocks, the next, you're up to your elbows in home equity agreements (HEAs). That's where Unlock Technologies finds itself. They've just wrapped up their ninth HEA securitization, a hefty $433.1 million, under the watchful eye of D2 Asset Management. This is no minor league...

Continue Reading
China's 15th Plan: Key Moves in the Capital Markets

Updated Category News Views 135

Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...

Continue Reading
Massive $1B Jobs Initiative Fights AI Automation Impact

Updated Category News Views 33

Initiative Tackles Economic Shifts Head-On AI and automation are turning the job market upside down, and more than 20 foundations and philanthropies are throwing their weight behind a $1 billion initiative called All In For Jobs. Their aim? Connect half a million Americans to stable, decent-paying jobs and prepare communities to face the daunting transition imposed by...

Continue Reading
HCLTech Partners with Rapidus on Semiconductor Future

Updated Category News Views 81

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...

Continue Reading

Top 5 Most Recently Viewed Articles

Unpacking the Rise of Pickleball: A Community Revolution

Updated Category News Views 221

The Rise of Pickleball: A Community Phenomenon Recently, pickleball has captured the hearts of many, becoming a vibrant part of community life. No longer just a novel backyard game, it’s now one of the most popular sports across the nation. The YMCA is playing a crucial role in this transformation, offering a welcoming space for players of all ages. What Makes...

Continue Reading
Graphex Group Secures Additional Time for NYSE Compliance

Updated Category News Views 98

Graphex Group: Navigating NYSE American Compliance Graphex Group Limited (“Graphex Group” or the “Company”) (NYSE American: GRFX) recently announced an important update regarding its compliance standing on the NYSE American Exchange. The company has received an extension, known as the Additional Cure Period, allowing it more time to meet the Exchange’s listing...

Continue Reading
Tenable's Leadership to Attend Key Technology Conferences

Updated Category News Views 159

Tenable's Upcoming Investor Engagements Tenable, a leader in exposure management, has announced participation in significant investor events where key executives will be present to share insights. This is an excellent opportunity for industry professionals to gain knowledge about the company's strategy and offerings in cybersecurity. Conferences to Attend Steve Vintz,...

Continue Reading
Tiryaki Syria Joins Forces with Syrian Fund to Boost Agri Sector

Updated Category News Views 3

Strategic Alliance in Syrian Agriculture Here's a move worth noting—Tiryaki Syria is shacking up with the Syrian Sovereign Fund in a deal that's more than just ink on paper. When a big player in the agri-commodity game decides to team up with a sovereign fund to bolster agriculture, it's bound to stir the pot. But to get this deal's nuances, you gotta strip away the...

Continue Reading
Empowering Women Entrepreneurs: A Competition Like No Other

Updated Category News Views 226

Empowering Women Entrepreneurs: A Competition Like No Other In Fort Worth, Texas, three ambitious women entrepreneurs are preparing themselves for an exciting competition that could potentially transform their businesses forever. They are aiming to secure part of a remarkable $42,500 in seed funding through a prestigious event that focuses on elevating female-led...

Continue Reading